| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-04-08 | Isis Pharmaceuticals (USA - CA) Roche (Switzerland) | antisense oligonucleotide (ASO) technology | Huntington's disease | development |
Genetic diseases - Neurodegenerative diseases - Rare diseases | Development agreement |
| 2013-04-08 | Vivalis (France) GSK (UK) | EB66® cell line | undisclosed viral disease | R&D |
Infectious diseases | Licensing agreement |
| 2013-04-04 | OncoDNA (Belgium) CollabRx (USA) | combined test and medical informatics solution | collaboration |
Cancer - Oncology | Services contract | |
| 2013-04-03 | Bachem (Switzerland) Axon Neuroscience (Slovak Republic) | finished dosage forms of peptide-protein conjugate targeting Alzheimer’s disease | Alzheimer’s disease | manufacturing |
Neurodegenerative diseases | Production agreement |
| 2013-04-03 | Crown Bioscience (USA) Horizon Discovery (UK) | X-MAN™ isogenic cell lines, in vivo models for drug discovery | R&D |
Technology - Services | R&D agreement | |
| 2013-04-02 | BiogenIdec (USA) Elan (Ireland) | Tysabri® (natalizumab) | multiple sclerosis | collaboration |
Autoimmune diseases - Neurodegenerative diseases | Collaboration agreement |
| 2013-04-02 | Bio-Modeling Systems (France) the Foundation FondaMental (France) | CADI™ model | bipolar disorders, schizophrenia | R&D |
CNS diseases - Mental diseases | R&D agreement |
| 2013-04-02 | Bind Biosciences (USA - MA), now Bind Therapeutics (USA - MA) | name change |
Cancer - Oncology | Establishment of a new subsidiary in the EU | ||
| 2013-04-01 | Aeterna Zentariis (Canada) Merck KGaA, Merck Serono (Germany) | Cetrotide® (cetrorelix acetate for injection) | manufacturing |
Woman's health | Production agreement | |
| 2013-03-28 | Reneuron (UK) Cell Therapy Catapult (UK) | cell therapy manufacturing technologies and assays | manufacturing production |
Regenerative medicine | ||
| 2013-03-27 | Medicyte (Germany) Life Technologies (USA) | Upcyte® cells | licensing |
Establishment of a new subsidiary in the EU | ||
| 2013-03-26 | Lundbeck (Denmark) Otsuka Pharmaceutical (Japan) | Lu AE58054 (idalopirdine) | Alzheimer's disease | development licensing commercialisation |
Neurodegenerative diseases | Licensing agreement |
| 2013-03-26 | Sanofi (France) Oncodesign (France) | Nanocyclix® technology | R&D licensing |
Cancer - Oncology | ||
| 2013-03-26 | Myriad Genetics (USA) PharmaMar (Spain) | homologous recombination deficiency (HRD) testing | collaboration |
Cancer - Oncology | Services contract | |
| 2013-03-26 | Jacobs Engineering Group (USA) Sanofi Pasteur (France) | Aguila II Project | services contract |
Infectious diseases | Services contract | |
| 2013-03-26 | Clinigen (UK) Novartis (Switzerland) | Cardioxane® (dexrazoxane) | prevention of the cardiotoxicity of anthracycline chemotherapy for patients with advanced and/or metastatic breast cancer | Cancer - Oncology | Product acquisition | |
| 2013-03-25 | Sanofi (France) Transgene (France) | immunotherapy products | collaboration |
Cancer - Oncology - Infectious diseases | Production agreement | |
| 2013-03-25 | The University of Nottingham (UK) Fusion IP (UK) | collaboration |
Collaboration agreement | |||
| 2013-03-22 | APO-T (The Netherlands) LinXis (The Netherlands) | fully-human antibody-drug-conjugates | development |
Cancer - Oncology | Development agreement | |
| 2013-03-22 | Affymetrix (USA) UK Biobank (UK) | collaboration |
Cardiovascular diseases - Cancer - Oncology - Metabolic diseases | Services contract |
